View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 17, 2021

Lung Cancer accounts for 16.0% share of global Oncology clinical trial activity in 2020

By Carmen

Lung C ancer accounted for a 16.0% share of the global clinical trials within the Oncology therapy area in 2020, registering an increase of 1.6% when compared with the last ten-year average of 14.4% share, according to GlobalData.

C hart1″ style=”width: 80%; height: 450px;”>
  • Embed this chart
    Embed this chart into your website C opy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Lung C ancer

Industry sponsored trials held a 43.0% share of all the clinical trials for Lung C ancer indication in 2020, registering an increase of 2.9% when compared with the ten-year average of 40.1%. Non-industry sponsored trials accounted for a 57.0% share in 2020, marking a decrease of 2.9% over the ten-year average of 59.9%.

C hart2″ style=”width: 80%; height: 450px;”>
  • Embed this chart
    Embed this chart into your website C opy and paste the code below into your website to display the chart.

Top regions of industry sponsored Lung C ancer trials

Asia-Pacific was the top region for industry sponsored Lung C ancer trials, accounting for a 65.8% share in 2020, when compared with the five-year average of 57.0% and ten-year average of 51.9%.

North America was at the second position with a 46.6% share in 2020, over the five-year average of 58.1% and ten-year average of 56.9%, followed by Europe with a 29.7% share in 2020, as against five-year and ten-year averages of 41.8% and 45.5% respectively.

Middle East and Africa stood fourth with a 7.3% share in 2020, compared with the five-year average of 8.4% and ten-year average of 7.9%, followed by South and C entral America with a 7.3% share in 2020, over five-year and ten-year averages of 7.4% and 6.7% respectively.

C hart3″ style=”width: 80%; height: 450px;”>
  • Embed this chart
    Embed this chart into your website C opy and paste the code below into your website to display the chart.

The US was the top country for industry sponsored Lung C ancer trials, accounting for a 46.3% share in 2020, as against the five-year average of 56.1% and ten-year average of 55.3%.

C hina held a 38.1% share in 2020, over the five-year average of 28.7% and ten-year average of 20.8%, followed by South Korea with a 16.7% share in 2020, compared with the five-year and ten-year averages of 16.2% and 16.8% respectively.

Spain held a 16.7% share in 2020, as against the five-year average of 26.3% and ten-year average of 24.9%.

France held a 13.6% share in 2020, over the five-year and ten-year averages of 19.3% and 20.6% respectively.

Top regions of non-industry sponsored Lung C ancer trials

Asia-Pacific was the top region for non-industry sponsored Lung C ancer trials, accounting for a 67.5% share in 2020 when compared with the five-year average of 60.4% and ten-year average of 61.1%.

North America was at the second position with a 19.3% share in 2020, over the five-year and ten-year averages of 25.5% and 24.8% respectively, followed by Europe with a 13.0% share in 2020, as against the five-year average of 14.0% and ten-year average of 13.9%.

Middle East and Africa stood at the fourth position with a 0.7% share in 2020, compared with the five-year average of 1.4% and ten-year average of 1.2%, followed by South and C entral America with a 0.7% share in 2020, over the five-year and ten-year averages of 0.9% and 0.7% respectively.

C hart4″ style=”width: 80%; height: 450px;”>
  • Embed this chart
    Embed this chart into your website C opy and paste the code below into your website to display the chart.

C hina was the top country for non-industry sponsored Lung C ancer trials, accounting for a 54.3% share in 2020, as against the five-year average of 37.1% and ten-year average of 26.6%.

The US held a 17.3% share in 2020, over the five-year average of 23.5% and ten-year average of 22.9%, followed by Japan with a 5.8% share, compared with the five-year and ten-year averages of 16.5% and 27.7% respectively.

South Korea held a 3.6% share in 2020, as against the five-year average of 4.1% and ten-year average of 3.9%.

France held a 2.9% share in 2020, over the five-year average of 3.5% and ten-year average of 3.2%.

Phase I trials lead industry sponsored clinical trials for Lung C ancer in 2020

Phase I trials held a 41.2% share of industry sponsored clinical trials for Lung C ancer in 2020, over the five-year average of 42.9% and ten-year average of 41.7%.

Phase II trials held a 39.8% share in 2020, as against the five-year average of 37.3% and ten-year average of 38.1%. Phase III trials held a 14.1% share in 2020, compared with the five-year and ten-year averages of 13.7% and 12.9% respectively.

Phase IV trials held a 4.9% share in 2020, over the five-year average of 6.1% and ten-year average of 7.3%.

Phase II trials lead non-industry sponsored clinical trials for Lung C ancer in 2020

Phase II trials held a 58.9% share of non-industry sponsored clinical trials for Lung C ancer in 2020, over the five-year average of 62.1% and ten-year average of 65.6%.

Phase IV trials held an 18.0% share in 2020, as against the five-year average of 15.1% and ten-year average of 11.6%. Phase I trials held a 16.8% share, compared with the five-year and ten-year averages of 15.5% and 15.2% respectively.

Phase III trials held a 6.3% share in 2020, over the five-year average of 7.3% and ten-year average of 7.5%.

Methodology: The clinical trials data used for the analyses were extracted from the C linical Trials Database of GlobalData’s Pharma Intelligence C enter. C linical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena